M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Avastin (Bevacizumab, RHUMAB VEGF)
Drug: Capecitabine
Radiation: Radiation Therapy

First Posted Date: 2005-06-07

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00113230

Locations: 🇺🇸
UT M. D. Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: Bevacizumab

First Posted Date: 2005-06-07

Last Posted Date: 2020-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00113217

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Glioblastoma Multiforme

Interventions: Drug: Celecoxib
Drug: Isotretinoin
Drug: Temozolomide
Drug: Thalidomide

First Posted Date: 2005-06-03

Last Posted Date: 2021-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 178

Registration Number: NCT00112502

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 9 locations

Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

Phase 3

Completed

Conditions: Neurotoxicity
Unspecified Childhood Solid Tumor, Protocol Specific
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alpha-lipoic acid
Other: placebo

First Posted Date: 2005-06-03

Last Posted Date: 2014-04-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 244

Registration Number: NCT00112996

Locations: 🇺🇸
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸
Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸
CCOP - Scott and White Hospital, Temple, Texas, United States

and more 10 locations

Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Campath-1H

First Posted Date: 2005-02-01

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00102661

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Fenretinide (4-HPR)
Drug: SCH66336

First Posted Date: 2005-02-01

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00102635

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Biological: Intraperitoneal tgDCC-E1A
Drug: Paclitaxel

First Posted Date: 2005-02-01

Last Posted Date: 2018-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00102622

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Phase 1

Active, not recruiting

Conditions: Recurrent Glioblastoma
Malignant Supratentorial Neoplasm
Recurrent Gliosarcoma

Interventions: Drug: Lonafarnib
Drug: Temozolomide

First Posted Date: 2005-02-01

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00102648

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Filgrastim
Biological: Pegfilgrastim
Biological: Rituximab
Drug: Cyclophosphamide
Drug: Pegylated liposomal doxorubicin hydrochloride
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2005-01-10

Last Posted Date: 2020-10-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00101010

Locations: 🇺🇸
CCOP - Grand Rapids, Grand Rapids, Michigan, United States
🇺🇸
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States

and more 4 locations

Trial of Curcumin in Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Neoplasms
Adenocarcinoma

Interventions: Drug: Curcumin

First Posted Date: 2004-10-19

Last Posted Date: 2020-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00094445

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy